-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Theravance Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2012 to 2024.
- Theravance Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2025 was $54.8M.
- Theravance Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2025 was $13M.
- Theravance Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$56.4M, a 2.22% decline from 2023.
- Theravance Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$55.2M, a 106% decline from 2022.
- Theravance Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $872M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)